Kymera Therapeutics stock price target lowered to $65 at Brookline Capital

Brookline Capital Markets adjusted its price target for Kymera Therapeutics (KYMR) to $65 from $70, while maintaining a Buy rating, primarily due to updated financial projections reflecting changes in cash position and an increased share count. Despite this minor reduction, the $65 target still represents significant upside from current trading levels, supported by the company's strong financial health and recent analyst bullishness from firms like Morgan Stanley and BofA. Kymera also recently announced a $250 million public stock offering to advance its clinical programs, signaling continued pipeline investment.

Analysis

Despite a headline price target reduction from Brookline Capital Markets to $65 from $70, the underlying analyst sentiment for Kymera Therapeutics (KYMR) remains strongly positive. The adjustment is attributed to technical changes in financial modeling, specifically an increased share count estimate of up to 7.8% for 2026-2035 and revised net interest income projections, rather than a deterioration in the company's core outlook. Crucially, Brookline maintained its "Buy" rating and left its long-term revenue and operating income forecasts for 2025-2035 unchanged. This specific revision is part of a broader, bullish consensus, with Morgan Stanley initiating coverage with an "Overweight" rating and a $70 target, and both BofA Securities and H.C. Wainwright recently raising their targets to $54 and $60, respectively. Kymera's strategic focus is on advancing its pipeline, supported by a recent $250 million public stock offering and positive developments such as Sanofi's decision to advance collaborator program KT-485 into clinical trials. The company's financial position appears robust, evidenced by a current ratio of 8.49 and a balance sheet holding more cash than debt.

Key Decisions for Investors

• Investors should look beyond the headline price target cut and focus on the reiterated 'Buy' rating and unchanged long-term revenue forecasts, which suggest the core investment thesis remains intact.
• The primary value drivers are pipeline developments, such as the STAT6 program and updates from the Sanofi collaboration, so these clinical milestones should be monitored as key catalysts.
• Consider the dilutive effect of the recent $250 million stock offering and updated share count forecasts, which directly impacted Brookline's valuation model, when assessing future earnings potential.
• Given the significant disconnect between the current trading price of $44.79 and the cluster of analyst price targets ranging from $54 to $70, current levels may represent a compelling entry point for those with a high-risk tolerance for clinical-stage biotech.